Blood-Brain Barrier Transporters
Mastering a CNS pharmacotherapy strategy to explore transporters to enhance drug delivery in the brain
In the Chair:
Dr. Janet Hoogstraate Director DMPK
Hear from your eminent Speaker Panel:
Dr. Anders Haegerstrand Vice President and Chief Scientific Officer
Dr. Lars U. Wahlberg Executive Vice President and Chief Operating Officer
Dr Mohammad S. Alavijeh Managing Director
Berend Oosterhuis, Director of Business Development and Contract Research Services
Dr. Björn Bauer Assistant Professor
UNIVERSITY OF MINNESOTA (USA)
Associate Professor Eric V. Shusta Department of Chemical & Biological Engineering
UNIVERSITY OF WISCONSIN-MADISON (USA)
Professor Jens Pahnke Head of the NRL and Head of the DZNE Biomarker and Autopsy Study
UNIVERSITY OF ROSTOCK
The World is facing tremendous challenges in the coming years with a rapidly aging population who might suffer from neurodegenerative conditions. This will be a burden for health services in many countries both economically and socially. To overcome these challenges, the Life Science industry and the academic community work in partnership to accelerate scientific discoveries to prevent or slow down the progression of Alzheimer’s disease and Parkinsons disease.
The super family ABC transporter proteins have come into CNS pharmacotherapy recently to facilitate the clearance of neurotoxic proteins. Age-related neurodegenerative disorders have in common the accumulation of insoluble neurotoxic proteins. Proteins that become toxic within the brain are detoxified or cleared from the brain. MDR1 and P-glycoprotein transporters represent a brand new master drug target for multidrug resistance from proteins. P-glycoprotein transporters possess capabilities to pump out beta-amyloid plaques through the blood-brain barrier to prevent an inflammatory response in the brain that could damage nerve cells. MDR1 and P-glycoprotein transporters are a new drug target strategy to enhance drug delivery to the brain in order to prevent or slow down the progression of dementia such as Alzheimer’s and Parkinsons disease.
This executive CNS event will examine the role of transporters to support a CNS pharmacotherapy strategy to deliver innovative treatment regimes to successfully combat Alzheimer’s and Parkinsons disease. Our distinguished speaker panel will provide your company with a road map to successfully draw up strategies to cross the BBB and enhance drug discovery in the human brain. This conference will enable your company to position itself as a frontrunner being able to launch safe and innovative CNS drug treatments for a growing population of elderly people the next decades.
This event will tackle key issues such as:
Target audience and Job titles:
Presidents, Chief Executive Officers, Chief Scientific Officers, Chief Medical Officers, Vice Presidents, Directors and Heads within: